PUMA BIOTECHNOLOGY, INC. License Agreements
14 Contracts & Agreements
- Exclusive License Agreement, dated September 16, 2022, by and between the Company and Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company... (Filed With SEC on November 3, 2022)
- Amendment No. 3 to the License Agreement, dated February 24, 2021, by and between the Company and Pierre Fabre Medicament SAS (Filed With SEC on May 6, 2021)
- Amendment No. 2 to License Agreement dated October 29, 2020, between the Company and Pfizer Inc (Filed With SEC on March 1, 2021)
- Second Amendment to the License Agreement, dated November 25, 2019, by and between the Company and Pierre Fabre Medicament SAS (Filed With SEC on February 28, 2020)
- First Amendment to the License Agreement, dated September 17, 2019, by and between the Company and Pierre Fabre Medicament SAS (Filed With SEC on February 28, 2020)
- Amendment to the License Agreement, dated December 18, 2019, by and between the Company and Knight Therapeutics, Inc (Filed With SEC on February 28, 2020)
- License Agreement, dated March 29, 2019, by and between the Company and Pierre Fabre Medicament SAS (Filed With SEC on May 10, 2019)
- License Agreement, dated January 9, 2019, by and between the Company and Knight Therapeutics Inc (Filed With SEC on March 1, 2019)
- Amendment No. 1, dated April 20, 2018, to the License Agreement by and between the Company and Specialised Therapeutics Asia Pte Ltd (Filed With SEC on August 9, 2018)
- License Agreement, dated March 30, 2018, between the Company and Pint Pharma International SA (Filed With SEC on May 10, 2018)
- License Agreement, dated November 20, 2017, by and between the Company and Specialised Therapeutics Asia Pte Ltd (Filed With SEC on March 9, 2018)
- Amendment No. 1 to License Agreement between Puma Biotechnology, Inc. and Pfizer Inc. (Filed With SEC on November 10, 2014)
- LICENSE AGREEMENT (Filed With SEC on December 16, 2011)
- LICENSE AGREEMENT (Filed With SEC on October 11, 2011)
